help button home button Am J Pathol ASIP 2008 Summer Academy, Molecular Methcanisms of Human Disease: Injury, Inflammation, and Tissue Repair
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lichy, J. H.
Right arrow Articles by Taubenberger, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lichy, J. H.
Right arrow Articles by Taubenberger, J. K.
(American Journal of Pathology. 1998;153:271-278.)
© 1998 American Society for Investigative Pathology

Regular Articles

Loss of Heterozygosity on Chromosome 11p15 during Histological Progression in Microdissected Ductal Carcinoma of the Breast

Jack H. Lichy, Maryam Zavar, Mark M. Tsai, Timothy J. O'Leary and Jeffery K. Taubenberger

From the Molecular Pathology Division, Department of Cellular Pathology, Armed Forces Institute of Pathology, Washington, D.C.

Microdissection of histologically identifiable components from formalin-fixed, paraffin-embedded tissue sections allows molecular genetic analyses to be correlated directly with pathological findings. In this study, we have characterized loss of heterozygosity (LOH) at chromosome 11p15 at different stages of progression in microdissected tumor components from 115 ductal carcinomas of the breast. Microdissected foci of intraductal, infiltrating, and metastatic tumors were analyzed to determine the stage of progression at which LOH at 11p15 occurs. LOH was detected in 43 (37%) of 115 cases. Foci of intraductal carcinoma could be microdissected from 85 cases, of which 30 (35%) showed LOH at some stage of progression. LOH was detected in the intraductal component in 26 of these 30 cases. Interstitial deletions were characterized by using a panel of 10 highly polymorphic markers. The smallest region of overlap (SRO) for LOH at 11p15 was bounded by the markers D11S4046 and D11S1758. LOH at 11p15.5 showed no correlation with estrogen receptor status, the presence of positive lymph nodes, tumor size, histological grade, or long-term survival. We conclude that 11p15 LOH usually occurs early in breast cancer development but less frequently does not develop until the infiltrating or metastatic stages of tumor progression.




This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
R. E. Ellsworth, D. L. Ellsworth, B. Deyarmin, L. R. Hoffman, B. Love, J. A. Hooke, and C. D. Shriver
Timing of Critical Genetic Changes in Human Breast Disease
Ann. Surg. Oncol., December 1, 2005; 12(12): 1054 - 1060.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. A. McCall, J. H. Lichy, K. E. Bijwaard, N. S. Aguilera, W.-S. Chu, and J. K. Taubenberger
Epstein-Barr Virus Detection in Ductal Carcinoma of the Breast
J Natl Cancer Inst, January 17, 2001; 93(2): 148 - 150.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
C. Washington, F. Dalbegue, F. Abreo, J. K. Taubenberger, and J. H. Lichy
Loss of Heterozygosity in Fibrocystic Change of the Breast : Genetic Relationship Between Benign Proliferative Lesions and Associated Carcinomas
Am. J. Pathol., July 1, 2000; 157(1): 323 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. F. Newsham
The Long and Short of Chromosome 11 in Breast Cancer
Am. J. Pathol., July 1, 1998; 153(1): 5 - 9.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society for Investigative Pathology.